Related Experiment Video
Updated: Aug 3, 2025

Modified Yeast-Two-Hybrid System to Identify Proteins Interacting with the Growth Factor Progranulin
Published on: January 17, 2012
Circulating progranulin in human infants: relation to prenatal growth and early postnatal nutrition
Marta Díaz1,2, Alberto Mestres-Arenas3,4, Carles Lerin1,2
1Pediatric Research Institute Sant Joan de Déu, University of Barcelona, 08950, Esplugues, Barcelona, Spain.
Insights
Progranulin (PGRN) levels increase in infants but less so in small for gestational age (SGA) infants. Lower PGRN in SGA infants is linked to metabolic risks, suggesting a role in future disease development.
Area of Science:
- Pediatric Endocrinology
- Metabolic Disease Biomarkers
- Infant Growth and Development
Background:
- Progranulin (PGRN) is implicated as a biomarker for metabolic diseases.
- Infants born small for gestational age (SGA) face increased risks for obesity and type 2 diabetes, particularly with formula feeding and rapid postnatal weight gain.
- Longitudinal assessment of PGRN in infants is crucial for understanding its role in early metabolic health.
Purpose of the Study:
- To longitudinally assess progranulin (PGRN) concentrations in infants born appropriate for gestational age (AGA) and small for gestational age (SGA).
- To investigate the relationship between PGRN levels, feeding mode (breast-fed vs. formula-fed), and metabolic health markers in early infancy.
- To explore the potential of PGRN as an early indicator of metabolic disease risk in SGA infants.
Main Methods:
- A cohort of 183 infants (AGA and SGA) were studied, divided by feeding mode (breast-fed or formula-fed) for the first 4 months.
- Measurements included auxology, glucose, insulin, IGF-1, adiponectin, PGRN, and body composition (DXA) at birth, 4 months, and 12 months.
- Statistical analyses correlated PGRN levels with auxological, metabolic, and body composition data.
Main Results:
- PGRN levels were low at birth and increased by 4 and 12 months, with a less pronounced increase observed in SGA infants.
- PGRN levels were independent of prenatal growth and feeding mode.
- PGRN concentrations correlated with markers of adiposity, inflammation, and insulin resistance, particularly in formula-fed SGA infants.
Conclusions:
- The attenuated rise in PGRN levels during infancy in SGA infants, coupled with its association with metabolic risk factors, suggests a potential role in future disease development.
- PGRN may be involved in the metabolic adaptations of SGA infants, potentially contributing to their heightened risk for obesity and type 2 diabetes.
- Further research is warranted to elucidate the precise role of PGRN in the metabolic trajectory of SGA infants.
Background:
Progranulin (PGRN) displays pleiotropic biological functions and has been proposed as a biomarker for metabolic diseases. We longitudinally assessed PGRN concentrations in infants born appropriate (AGA) or small for gestational age (SGA), the latter being at risk for obesity and type 2 diabetes, especially if they experience an excessive postnatal catch-up in weight and are formula-fed (FF).
Methods:
The study population consisted of 183 infants who were exclusively breast-fed [(BF), AGA, n = 66; SGA, n = 40], or FF (AGA, n = 31; SGA, n = 46) over the first 4 months. Assessments included auxology, fasting glucose, insulin, IGF-1, high-molecular-weight adiponectin, PGRN and body composition (by DXA), at birth, and at age 4 and 12 months.
Results:
PGRN levels were low at birth and unaffected by prenatal growth. PGRN increased at 4 and 12 months, although to a lesser extent in SGA infants, and was unrelated to the mode of feeding. PGRN correlated with markers of adiposity, inflammation and insulin resistance in both AGA and SGA infants, especially in those FF.
Conclusions:
The attenuated increase of PGRN levels in SGA infants over the first year of life, along with the association to markers of unhealthy metabolic profile, might point to a role of PGRN in future disease risks.
Impact:
Progranulin (PGRN) displays pleiotropic biological functions and has been proposed as a biomarker for metabolic diseases. In healthy infants, PGRN concentrations are low at birth and experience a significant and progressive increase up to age 12 months, which is less marked in infants born small for gestational age (SGA) and is unrelated to the mode of feeding. Circulating PGRN is related to markers of adiposity, inflammation, and insulin sensitivity, especially in formula-fed SGA infants. PGRN may play a role in the metabolic adaptations of SGA infants during early life, potentially contributing to the risk for obesity and type 2 diabetes in this population.
More Related Videos
Related Concept Videos
Nature and Nurture
Anatomy of the Intestines
Small Intestines
The small intestine is an ~7 meter-long tube with an inner diameter of just 2.5 cm. Since most nutrients are absorbed here, the inner lining of the...

